Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 572 participants.

Also called NCT07253181

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 572 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07253181
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07253181. Randomized; single masking; primary purpose treatment. Start 2026-01-06 (actual); primary completion 2028-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
Acronym
TREASURE
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Condition
Transportation of Patients
Intervention (Drug)
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Lead sponsor
Xuanwu Hospital, Beijing (class: other)
Collaborator
Boehringer Ingelheim (China) Investment Co., Ltd (class: not stated)
Collaborator
Jeffrey Saver (class: not stated)
Collaborator
Maarten Lansberg (class: not stated)
Collaborator
Thanh N. Nguyen (class: not stated)
Collaborator
Pierre Seners (class: not stated)
Collaborator
Jens Fiehler (class: not stated)
Collaborator
Raul G. Nogueira (class: not stated)

Record details

Record id
cardio:ct-nct07253181
Content hash
7c50cce24cd346b9d926eadc91690d4bcb6dc59036f4c5c111dfda3cf3d222b5